Institute of Director's Roger Barker says the Pfizer bid for Astrazeneca has prompted significant political intervention.
He said Pfizer's pursuit of Astrazeneca has stirred up a wealth of protectionism, even if it's a global company.
Ultimately the decision is in the hands of the shareholders who must consider the deal carefully.
